ArticleNpj imaging2026
Homogeneous image-based digital immunoassays with high error tolerance.
Article in Npj imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a significant global health need to translate more in vitro diagnostic tests from clinical laboratories to field-based applications, including point-of-care and self-administered test formats. These applications typically require smaller sample sizes, limit sample processing and measurement capabilities, and introduce greater handling variability. Error tolerance is one of the most critical factors for successful field-based assay design. Here, we examine machine-learning (ML) strategies to enhance the error tolerance of image-based nanoparticle immunoassays. Random dispersions of nanoparticles were imaged in microliter sample volumes, and images were processed to determine analyte concentrations based on nanoparticle appearance. Assay performance was characterized using two common blood analytes: C-reactive protein and anti-SARS-CoV-2 IgG. We compare the results from conventional image analysis, a hybrid ML-conventional approach based on pixel segmentation, and end-to-end image regression using a targeted regularization strategy. Using serum samples from SARS-CoV-2 positive individuals, the segmentation-based approach enabled binary classification with 96% specificity and 90% sensitivity, matching seroconversion rates. The end-to-end regression model achieved superior quantitative performance (5.2 ng/mL), approaching ELISA-level detection range (0.01-10 ng/mL, depending on capture antibody affinity) in a single 30 min workflow without sample preprocessing. The limit of detection for digital molecular assays is not fixed, and we perform a theoretical analysis showing how adjusting particle counts and polydispersity can achieve arbitrary sensitivity down to the Poisson limit. Training images for the full image regression approach required only a single label-the analyte concentration-eliminating labor-intensive pixel-level labeling. Ultimately, the image-based readouts significantly improved dynamic range, sensitivity, and reproducibility over conventional readouts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.